Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove

Assessing Genomic Alteration in Non-Squamous Non-Small Cell Lung Cancer Patients

September 8th, 2023
1,2,3,4,5, 1,2,3,4, 1,2,3,4, 1,2,3,4, 1,2,3,4, 1,2,3,4, 1,2,3,4, 1,2,3,4, 3,4,5,6, 3,4,5,6, 1,2,3,4,5, 1,2,3,4,5, 1,2,3,4,5
1Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, CHU de Nice, 2Hospital-Integrated Biobank (BB-0033-00025), Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 3Institut Hospitalo-Universitaire (IHU), RespirERA, Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 4FHU OncoAge, Université Côte d'Azur, 5Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Centre Antoine-Lacassagne, Université Côte d'Azur, 6Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur

Summary
Automatic Translation

L'aumento dei biomarcatori molecolari da testare per la gestione della cura del carcinoma polmonare non squamoso non a piccole cellule (NS-NSCLC) ha spinto lo sviluppo di metodi di rilevamento molecolare rapidi e affidabili. Descriviamo un flusso di lavoro per la valutazione dell'alterazione genomica per i pazienti NS-NSCLC utilizzando un approccio di sequenziamento di nuova generazione (NGS) ultraveloce.

Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter